Compare Boston Scientific Corporation (BSX) vs T Rowe Price Group Inc (TROW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Scientific Corporation vs T Rowe Price Group Inc — how do they compare? Boston Scientific Corporation trades at $42.6 (market cap $66.37B), while T Rowe Price Group Inc trades at $116.1 (market cap $24.87B). The key difference: Boston Scientific Corporation is far larger — about 2.7× T Rowe Price Group Inc's market cap, and T Rowe Price Group Inc pays a 4.48% dividend while Boston Scientific Corporation pays none. Which is the better fit depends on your goals.
| BSX | TROW | |
|---|---|---|
Market Cap | $66.37B | $24.87B |
Sector | Health | Financials |
52-Week High | $108.14 | $120.16 |
52-Week Low | $42.63 | $86.19 |
Enterprise Value | $75.94B | $21.58B |
Dividend Yield | — | 4.48% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $44.65, down 0.27% with bearish technical signals despite strong fundamentals. The company delivered three consecutive earnings beats with Q3-Q1 2026 EPS exceeding expectations, while revenue grew to $20.07B in 2025 with improving profit margins. Technical indicators show bearish momentum with support at $44 and resistance at $45, though Wall Street maintains 88% buy rating with $70.20 consensus target.
BSX presents a compelling value opportunity with attractive valuation multiples (P/E 18.68, P/S 3.24) and robust financial health, though near-term headwinds include competitive pressures in key segments and recent stock price decline of nearly 60% from 2025 highs. The strong analyst consensus suggests significant upside potential if execution improves.
T. Rowe Price (TROW) trades at $113.65, down 4.13% on the day, with a bullish technical signal from moving averages but neutral oscillators. The company reported June 2026 AUM of $1.89 trillion (PRNewsWire, 2026-07-13), showing steady growth. Recent earnings beat expectations in Q1 2026 with EPS of $2.52 versus $2.33 forecast. Valuation ratios remain attractive with a P/E of 12.19 and ROE of 19.31%, supported by strong cash flow trends.
TROW presents a mixed outlook: analyst consensus is cautious with 63% hold ratings and a $109.17 price target below current levels, but fundamentals like rising net cash flow to $909M in 2026 and a 28.28% net margin offer stability. Key risks include equity outflows and market volatility, while the dividend yield near 4.9% (Investors Business Daily, 2026-06-10) provides income appeal. Upside depends on sustained AUM growth and execution against competition.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →About T Rowe Price Group Inc
T. Rowe Price provides asset-management services for individual and institutional investors. It offers a broad range of no-load U.S. and international stock, hybrid, bond, and money market funds. At the end of August 2022, the firm had $1.339 trillion in managed assets, composed of equity (54%), balanced (30%), fixed-income (13%), and alternatives (3%) offerings. Approximately two thirds of the company's managed assets are held in retirement-based accounts, which provides T. Rowe Price with a somewhat stickier client base than most of its peers. The firm also manages private accounts, provides retirement planning advice, and offers discount brokerage and trust services. The company is primarily a U.S.-based asset manager, deriving just under 10% of its AUM from overseas.
Read more on TROW →
